Results 81 to 90 of about 29,631 (205)
Adverse events following immunization after each administered BNT162b2 dose.
, 2022 Adverse events following immunization after each administered BNT162b2 dose.
Irene Antonieta Barco-Flores (12184314) +11 more
core +1 more source
Vaccine: X, 2023 During spring 2021, AZD1222 and BNT162b2 were used as prime and BNT162b2 as booster COVID-19 vaccines in Denmark. We obtained self-reported information on systemic reactogenicity day-by-day during two weeks for 2862 healthcare workers vaccinated with ...
Sorosh Tabatabaeifar +6 more
doaj +1 more source
Vaccinations During Pregnancy Protect the Mother–Infant Dyad and Are Generally Safe
Acta Paediatrica, EarlyView.ABSTRACT Aim Vaccination in pregnancy has a critical impact on mothers, foetuses and infants. The aim of this paper was to summarise key points presented by experts attending the 12th Maria Delivoria‐Papadopoulos Perinatal Symposium in March 2025 and further expand and update them.
Ariadne Malamitsi‐Puchner +2 more
wiley +1 more source
Keratoplasty Rejection After the BNT162b2 messenger RNA Vaccine
Cornea, 2021 Purpose: The aim of this report was to report 2 patients who presented with acute corneal graft rejection 2 weeks after receiving the BNT162b2 messenger RNA (mRNA) vaccine for severe acute respiratory syndrome coronavirus 2.
Lauren M, Wasser +4 more
openaire +3 more sources
Alimentary Pharmacology &Therapeutics, EarlyView.In 59,946 chronic hepatitis B patients followed over 23 years, COVID‐19 vaccination rollout was temporally associated with a 56% increase in HBsAg loss rates (peak 1.27 per 100 person‐years in 2022), followed by gradual waning. Negative control outcomes showed no similar pattern, supporting biological specificity. ABSTRACT Background and Aims Hepatitis
Jonggi Choi +6 more
wiley +1 more source
, 2021 Vaccination development and production was an essential question for the prevention and global control of COVID-19. The strong support from governing authorities such as Operation Warp Speed and robust funding has led to the development and authorization
Khehra, Nimrat +5 more
core +1 more source
Humoral Immune Response of BNT162b2 and CoronaVac Vaccinations in Hemodialysis Patients: A Multicenter Prospective Cohort [PDF]
, 2022 The CoronaVac vaccine is the most used anti-SARS-CoV-2 vaccine worldwide. Previous data indicate that this vaccine produces a lower immune response than RNA vaccines such as BNT162b2.
Gajardo, Cynthia +33 more
core +1 more source
Vaccines, 2023 To compare immunogenicity and reactogenicity of five COVID-19 vaccine regimens against wild-type SARS-CoV-2 and variants of concern (VoCs) among Thai populations, a prospective cohort study was conducted among healthy participants aged ≥18 years who had ...
Tavitiya Sudjaritruk +12 more
doaj +1 more source
HIV Medicine, EarlyView.Abstract Background The potent immunogenicity of mRNA vaccination raised concerns about its impact on HIV‐1 viral load (VL) and reservoir size in people with HIV, which could drive vaccine hesitancy. As part of a prospective clinical trial, we investigated whether SARS‐CoV‐2 mRNA vaccination induced changes in VL and reservoir size after a 1‐year three‐
Oscar Kieri +8 more
wiley +1 more source
, 2023 Introduction: Data regarding inactivated vaccines for SARS-CoV-2 in patients undergoing maintenance hemodialysis (MHD) are limited. We aimed to investigate humoral responses induced by CoronaVac compared to BNT162b2 in this population.
TUĞCU, MURAT +1 more
core +1 more source